The body says that they have received little feedback from approved applications
Sahpra launched the programme to ensure that approved products reach the patients and that illicit formulations and veterinary products are not used
The South African Health Products Regulatory Authority (Sahpra) says that they have seen a decline in applications for their ivermectin Controlled Compassionate Use Access programme for Covid-19.
“The application numbers were higher in February and March but have significantly declined since then,” Saphra spokesperson Yuven Gounden told Health24.
The programme was launched at the end of January this year as various doctors lobbied for the drug to treat Covid-19. So far, Sahpra has approved 160 out of 214 applications since the start of the programme.